<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873479</url>
  </required_header>
  <id_info>
    <org_study_id>ASLAT20210430</org_study_id>
    <nct_id>NCT04873479</nct_id>
  </id_info>
  <brief_title>Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery</brief_title>
  <official_title>Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery:a Single Center, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Nankai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Nankai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, controlled design. In this study, low doses of&#xD;
      S-ketamine were selected for surgury treatment in septic patients under general anesthesia ,&#xD;
      Meanwhile, activity of HO-1 protein , oxidative stress and inflammatory markers in serum are&#xD;
      measured to evaluating the effects of S-ketamine Anesthetic on inflammatory response in&#xD;
      septic patients undergoing abdominal surgury. In addition,It is very necessary to make use of&#xD;
      the advantages of low-dose S-ketamine in anti-inflammation, and avoid the side effects of&#xD;
      mental symptoms, so as to guide the new direction of perioperative clinical application of&#xD;
      S-ketamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Title: Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients&#xD;
           Undergoing Abdominal Surgery&#xD;
&#xD;
        2. Research center: Single Center&#xD;
&#xD;
        3. The Design of the study: Randomized,double-blind, Controlled Trial&#xD;
&#xD;
        4. The population of the study: The main inclusion criteria are 18 years old or&#xD;
           above,Patients with sepsis who need surgical treatment under general anesthesia and&#xD;
           should be transferred to ICU for further treatment after surgery&#xD;
&#xD;
        5. Sample size: Enroll 50 patients (25 patients in each group)&#xD;
&#xD;
        6. Interventions: Participants in the test group received midazolam 0.05-0.1mg /kg,&#xD;
           sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine&#xD;
           0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil&#xD;
           0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of&#xD;
           sevoflurane at 2-3%.&#xD;
&#xD;
           while participants in the control group was the same as the test group except for&#xD;
           received the same volume of saline instead of S-ketamine.&#xD;
&#xD;
           Intraoperative cisatracurium and sufentanil were added according to the&#xD;
           circumstances.Bispectral index (BIS) was used to monitor the depth of anesthesia in two&#xD;
           groups, and the BIS value was controlled to be 40-60, and the dose was adjusted&#xD;
           according to the depth of anesthesia.&#xD;
&#xD;
        7. The aim of the research: To investigate the effect of S-ketamine Anesthetic on&#xD;
           Inflammatory Response in Septic Patients Undergoing Abdominal Surgery&#xD;
&#xD;
        8. Outcome# 1) Primary outcome# the incidence of postoperative pulmonary complications&#xD;
           2)Secondary outcome#Inflammatory indicators: leukocyte, CRP, PCT levels;Inflammatory&#xD;
           factors: IL-6, TNF-α, CC-16,activity of HO-1;Imaging diagnosis,such as chest&#xD;
           X-ray,ultrasound;therapies for respiratory insufficiency,such as nasal cannula,face&#xD;
           mask,postoperative noninvasive ventilation, re-intubation with postoperative mechanical&#xD;
           ventilation;Incidence of postoperative adverse reactions such as restlessness, delirium,&#xD;
           salivation, nausea, vomiting, respiratory depression, dizziness, etc;Length of stay in&#xD;
           ICU&#xD;
&#xD;
        9. The estimated duration of the study#1-2years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of postoperative pulmonary complications</measure>
    <time_frame>an average of 1 week</time_frame>
    <description>such as pneumonia,atelectasis ,pleural effusion,respiratory insufficiency,etc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory indicators: leukocyte, CRP, PCT levels</measure>
    <time_frame>an average of 1 day</time_frame>
    <description>leukocyte, CRP, PCT levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory factors</measure>
    <time_frame>an average of 1 day</time_frame>
    <description>IL-6, TNF-α, CC-16,activity of HO-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>imaging diagnosis</measure>
    <time_frame>an average of 1 week</time_frame>
    <description>chest X-ray,ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>therapies for respiratory insufficiency</measure>
    <time_frame>an average of 1 week</time_frame>
    <description>nasal cannula,face mask,postoperative noninvasive ventilation, re-intubation with postoperative mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative adverse reactions</measure>
    <time_frame>an average of 1 week</time_frame>
    <description>such as restlessness, delirium, salivation, nausea, vomiting, respiratory depression, dizziness, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>an average of 1 month</time_frame>
    <description>The time from the patient's surgery to leave the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>an average of 1 day</time_frame>
    <description>consumption of sufentanil and remifentanil</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sepsis</condition>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.2-0.3ug/kg,Etomidate 0.2-0.3mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.1-0.3ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-ketamine</intervention_name>
    <description>Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.</description>
    <arm_group_label>test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with sepsis requiring surgical treatment under general anesthesia should be&#xD;
             transferred to ICU with endotracheal intubation for further treatment after surgery&#xD;
&#xD;
          -  18≤ age ≤85, gender and nationality is not limited&#xD;
&#xD;
          -  Agree to participate in this study and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Declined to participate in this study&#xD;
&#xD;
          -  Patients in pregnancy or with drug allergy in this study&#xD;
&#xD;
          -  Patient had chronic or acute respiratory ailments&#xD;
&#xD;
          -  long-term preoperative continuous ventilatory support or oxygen dependency&#xD;
&#xD;
          -  Patients are now being included in another study&#xD;
&#xD;
          -  In the opinion of the attending physician or researcher, there are other conditions&#xD;
             that are not appropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianbo Yu MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Nankai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianbo Yu MD PhD</last_name>
    <phone>86-22-27435873</phone>
    <email>yujianbo11@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Nankai Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Jianbo, Professor</last_name>
      <phone>（022）27435008</phone>
      <phone_ext>（022）27435027</phone_ext>
      <email>yujianbo11@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Trimmel H, Helbok R, Staudinger T, Jaksch W, Messerer B, Schöchl H, Likar R. S(+)-ketamine : Current trends in emergency and intensive care medicine. Wien Klin Wochenschr. 2018 May;130(9-10):356-366. doi: 10.1007/s00508-017-1299-3. Epub 2018 Jan 10. Review. Erratum in: Wien Klin Wochenschr. 2018 Sep;130(17-18):557.</citation>
    <PMID>29322377</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Bustamante A, Frendl G, Sprung J, Kor DJ, Subramaniam B, Martinez Ruiz R, Lee JW, Henderson WG, Moss A, Mehdiratta N, Colwell MM, Bartels K, Kolodzie K, Giquel J, Vidal Melo MF. Postoperative Pulmonary Complications, Early Mortality, and Hospital Stay Following Noncardiothoracic Surgery: A Multicenter Study by the Perioperative Research Network Investigators. JAMA Surg. 2017 Feb 1;152(2):157-166. doi: 10.1001/jamasurg.2016.4065.</citation>
    <PMID>27829093</PMID>
  </reference>
  <reference>
    <citation>Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Review. Erratum in: Pharmacol Rev. 2018 Oct;70(4):879.</citation>
    <PMID>29945898</PMID>
  </reference>
  <reference>
    <citation>Welters ID, Feurer MK, Preiss V, Müller M, Scholz S, Kwapisz M, Mogk M, Neuhäuser C. Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth. 2011 Feb;106(2):172-9. doi: 10.1093/bja/aeq341. Epub 2010 Dec 7.</citation>
    <PMID>21138901</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Nankai Hospital</investigator_affiliation>
    <investigator_full_name>Jianbo Yu</investigator_full_name>
    <investigator_title>Department of anesthesiology , Director, Chief physician</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>acute lung injury</keyword>
  <keyword>S-ketamine</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

